Hence, DMF is not only an activator but also an inhibitor of Nrf2 and DJ-1, and it could be useful for the design of a new therapeutic strategy for the treatment of different types of cancers, including RCC [90]. This evidence concerns the gene PARK7 and renal cell carcinoma.